Therapy-related acute myeloid leukaemia with t(8;16)(p11;p13);MOZ-CBP and polymorphisms in detoxifying and DNA repair genes

Leukemia

Volumn 23, Issue 6, 2009, Pages 1164-1167

  Boyd, W N ^a   Bench, A J ^a   Vaghela, K J ^a   Campbell, G N ^b   Chowdhury, F B ^a   Gudgin, E J ^a   Scott, M A ^a   Erber, W N ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b IPSWICH HOSPITAL NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 1A1; CYTOTOXIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; GYRASE INHIBITOR; HYBRID PROTEIN; METHOTREXATE; MITOXANTRONE; MOZ CBP FUSION PROTEIN; NAVELBINE; OXIDOREDUCTASE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; QUINONE OXIDOREDUCTASE; RAD51 PROTEIN; TAMOXIFEN; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC1 PROTEIN; XRCC3 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLELIC IMBALANCE; ARTICLE; BREAST CARCINOMA; CASE REPORT; CHROMOSOME TRANSLOCATION; DETOXIFICATION; DNA POLYMORPHISM; ENZYME ACTIVITY; ENZYME BINDING; ENZYME POLYMORPHISM; GENE DELETION; GENE FUSION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; HEREDITY; HUMAN; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; RISK FACTOR; THERAPY RELATED ACUTE GRANULOCYTIC LEUKEMIA;

EID: 67349133163     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.383     Document Type: Article

References (17)

1. Leone G, Mele L, Pulsoni A, Equitani F, Pagano L. The incidence of secondary leukemias. Haematologica 1999; 84: 937-945.
2. Seedhouse C, Russell N. Advances in the understanding of susceptibility to treatment-related acute myeloid leukaemia. Brit J Haematol 2007; 137: 513-529.
3. Ellis NA, Huo D, Yildiz O, Worrillow LJ, Banerjee M, Le Beau MM et al MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood 2008; 112: 741-749.
4. Allan JM, Wild CP, Rollinson S, Willett EV, Moorman AV, Dovey GJ et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci USA 2001; 98: 11592-11597.
5. Campone M, Roché H, Kerbrat P, Bonneterre J, Romestaing P, Fargeot P et al. Secondary leukaemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group. Ann Oncol 2005; 16: 1343-1351.
6. Mistry AR, Felix CA, Whitmarsh RJ, Mason A, Reiter A, Cassinat B et al. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. New Engl J Med 2005; 352: 1529-1538.
7. Bolufer P, Barragan E, Collado M, Cervera J, López JA, Sanz MA. Influence of genetic polymorphisms on the risk of developing leukemia and on disease progression. Leuk Res 2006; 30: 1471-1491.
8. Panagopoulous I, Isaksson M, Lindvall C, Björkholm M, Ahlgren T, Fioretos T et al. RT-PCR analysis of the MOZ-CPB and CBP-MOZ chimeric transcripts in acute myeloid leukemias with t(8;16)(p11;p13). Gene Chromosome Canc 2000; 28: 415-424.
9. Seedhouse C, Faulkner R, Ashraf N, Das-Gupta E, Russell N. Polymorphisms in genes involved in homologous recombination repair interact to increase risk of developing acute myeloid leukaemia. Clin Cancer Res 2004; 10: 2675-2680.
10. Allan JM, Smith AG, Wheatley K, Hills RK, Travis LB, Hill DA et al Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood 2004; 104 3872-3877.
11. Cascorbi I, Brockmöller J, Roots I. A C4887A polymorphism in exon 7 of human CYP1A1: Population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res 1996; 56: 4965-4969.
12. Harth V, Donat S, Ko Y, Abel J, Vetter H, Brüning T. NAD(P)H quinone oxidoreductase 1 codon 609 polymorphism and its association to colorectal cancer. Arch Toxicol 2000; 73: 528-531.
13. Voso MT, D'Alo' F, Putzulu R, Mele L, Scardocci A, Chiusolo P et al Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. Blood 2002; 100: 2703-2707.
14. Wilson MH, Grant PJ, Hardie LJ, Wild CP. Glutathione S-transferase M1 null genotype is associated with a decreased risk of myocardial infarction. FASEB J 2000; 14: 791-796.
15. Levy-Lahad E, Lahad A, Eisenberg S, Dagan E, Paperna T, Kasinetz L et al. A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc Natl Acad Sci USA 2001; 98: 3232-3236.
16. Seedhouse C, Bainton R, Lewis M, Harding A, Russell N, Das-Gupta E. The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia. Blood 2002; 100: 3761-3766.
17. Worrillow LJ, Travis LB, Smith AG, Rollinson S, Smith AJ, Wild CP et al. An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating agents. Clin Cancer Res 2003; 9: 3012-3020.